GPR35 and colon carcinoma: Besides its potential as a pharmacological target, a recent study suggests that the expression of a GPR35 splice variant (GPR35 V2/3) in colon carcinoma patients might be useful as an indicator of poor prognosis [126], although further studies should be performed to establish its value as a prognostic factor.